Rabbit Recombinant Monoclonal RRM1 antibody. Suitable for IHC-P, WB, ICC/IF, Flow Cyt (Intra) and reacts with Human, Mouse, Rat samples. Cited in 18 publications.
View Alternative Names
RR1, RRM1, Ribonucleoside-diphosphate reductase large subunit, Ribonucleoside-diphosphate reductase subunit M1, Ribonucleotide reductase large subunit
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RRM1 antibody [EPR8483] (AB137114)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human lung carcinoma tissue sections labeling RRM1 with purified ab137114 at 1/1000 dilution (0.95 µg/ml). Perform heat mediated antigen retrieval using ab93684 (Tris/EDTA buffer, pH 9.0). ImmunoHistoProbe one step HRP Polymer (ready to use) was used as the secondary antibody. Negative control : PBS instead of the primary antibody. Hematoxylin was used as a counterstain.
- ICC/IF
AbReview32463****
Immunocytochemistry/ Immunofluorescence - Anti-RRM1 antibody [EPR8483] (AB137114)
Unpurified ab137114 (1/200) staining RRM1 in Hela cells (green). Cells were fixed in paraformaldehyde, permeabilised in 0.5%Triton X-100/PBS and counterstained with DAPI in order to highlight the nucleus (red). For further experimental details please refer to Abreview.
Image courtesy of an Abreview submitted by Dr. Kirk McManus, Univ. of Manitoba/Cancer Care MICB, Canada
- Flow Cyt (Intra)
Lab
Flow Cytometry (Intracellular) - Anti-RRM1 antibody [EPR8483] (AB137114)
unpurified ab137114 staining RRM1 in the human cell line HeLa (human cervix adenocarcinoma) by intracellular flow cytometry. Cells were fixed with 4% paraformaldehyde, permiabilised with 90% methanol and the sample was incubated with the primary antibody at a dilution of 1/100. A goat anti rabbit IgG (Alexa Fluor® 488) at a dilution of 1/2000 was used as the secondary antibody.
Isoytype control : Rabbit monoclonal IgG (Black)
Unlabelled control : Cell without incubation with primary antibody and secondary antibody (Blue)
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RRM1 antibody [EPR8483] (AB137114)
Immunohistochemical analysis of paraffin-embedded Human lung carcinoma tissue labelling RRM1 with unpurified ab137114 at 1/100 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
- ICC/IF
Unknown
Immunocytochemistry/ Immunofluorescence - Anti-RRM1 antibody [EPR8483] (AB137114)
Immunocytochemistry/ Immunofluorescence analysis of HT-29 (Human colorectal adenocarcinoma epithelial cell) cells labeling RRM1 with purified ab137114 at 1/100 dilution (9.5 µg/ml). Cells were fixed in 4% Paraformaldehyde and permeabilized with 0.1% tritonX-100. Cells were counterstained with ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) 1/200 (2.5 µg/ml). Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) was used as the secondary antibody at 1/1000 (2 µg/ml) dilution. DAPI (blue) was used as nuclear counterstain. PBS instead of the primary antibody was used as the secondary antibody only control.
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RRM1 antibody [EPR8483] (AB137114)
Immunohistochemical analysis of paraffin-embedded Human colon carcinoma tissue labelling RRM1 with ab137114 at 1/100 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
- WB
Lab
Western blot - Anti-RRM1 antibody [EPR8483] (AB137114)
All lanes:
Western blot - Anti-RRM1 antibody [EPR8483] (ab137114) at 1/10000 dilution
Lane 1:
HT-29 (Human colorectal adenocarcinoma epithelial cell) whole cell lysates at 20 µg
Lane 2:
A549 (Human lung carcinoma epithelial cell) whole cell lysates at 20 µg
Lane 3:
Mouse colon lysates at 20 µg
Lane 4:
Rat brain lysates at 20 µg
Lane 5:
Rat colon lysates at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 90 kDa
Observed band size: 90 kDa
false
- WB
Unknown
Western blot - Anti-RRM1 antibody [EPR8483] (AB137114)
All lanes:
Western blot - Anti-RRM1 antibody [EPR8483] (ab137114) at 1/10000 dilution
Lane 1:
HT29 cell lysate at 10 µg
Lane 2:
A549 cell lysate at 10 µg
Lane 3:
MCF7 cell lysate at 10 µg
Lane 4:
HeLa cell lysate at 10 µg
Secondary
All lanes:
Standard HRP-labeled goat anti-rabbit at 1/2000 dilution
Predicted band size: 90 kDa
true
- WB
CiteAb
Western blot - Anti-RRM1 antibody [EPR8483] (AB137114)
RRM1 western blot using anti-RRM1 antibody [EPR8483] ab137114. Publication image and figure legend from Zhou, J., Zhang, L., et al., 2020, Cancer Med, PubMed 31823522.
ab137114 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab137114 please see the product overview.
Expression of RRM1, STIM1, and TRIM21 was associated with the level of acquired gemcitabine (GEM) resistance. A, Venn diagram showed the top 20 consistently upregulated mRNAs in both GEM-resistant cell lines. B, Six intersected genes selected from among the top 20 consistently upregulated mRNAs. C and D, Total RNA and cytoplasmic proteins were extracted from BxPC-3, BxPC-3-GR, CFPAC-1, and CFPAC-1-GR. mRNA and protein expression levels of RRM1, STIM1, and TRIM21 were determined by quantitative reverse-transcription polymerase chain reaction and western blot analysis. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a control. E and F, RRM1, STIM1, and TRIM21 protein expression levels were measured by western blot analysis in both parental cell lines and their derived GEM subclones. GAPDH was used as a control. G, RRM1, STIM1, and TRIM21 protein expression levels among normal pancreatic and pancreatic cancer (PC) cell lines were evaluated by western blot analysis. GAPDH was used as a control. H, Histogram shows IC50 values for GEM in AsPC-1, BxPC-3, CFPAC-1, MIA PaCa-2, and PANC-1 cell lines. **p < .01, ***p < .001; comparisons indicated by lines
false
Related conjugates and formulations (2)
-
660 APC
APC Anti-RRM1 antibody [EPR8483]
-
Anti-RRM1 antibody [EPR8483] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The large subunit of ribonucleotide reductase contributes to the enzymatic function through binding and activation of smaller subunits including RRM2 and RRM2B forming a complex. This complex is important for maintaining balanced deoxyribonucleotide pools during the S-phase of the cell cycle. Proper RRM1 function ensures the fidelity of DNA synthesis impacting genomic stability and cell viability.
Pathways
RRM1 acts within the DNA replication and repair pathways. It interacts with the tumor suppressor protein p53 which modulates its activities in response to DNA damage. Through pathways like the p53-dependent checkpoint RRM1 contributes to DNA damage response mechanisms. This interaction with p53 and involvement in the DNA replication pathway highlight its centrality in maintaining genomic integrity.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (18)
Recent publications for all applications. Explore the full list and refine your search
Cell death & disease 16:161 PubMed40055335
2025
Applications
Unspecified application
Species
Unspecified reactive species
EBioMedicine 95:104752 PubMed37572644
2023
Applications
Unspecified application
Species
Unspecified reactive species
Journal of molecular and cellular cardiology 175:1-12 PubMed36470336
2022
Applications
Unspecified application
Species
Unspecified reactive species
Communications biology 5:571 PubMed35681099
2022
Applications
Unspecified application
Species
Unspecified reactive species
Heliyon 8:e09643 PubMed35711974
2022
Applications
Unspecified application
Species
Unspecified reactive species
Scientific reports 11:13474 PubMed34188151
2021
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in molecular biosciences 7:586146 PubMed33134322
2020
Applications
Unspecified application
Species
Unspecified reactive species
Oncotarget 11:2906-2918 PubMed32774771
2020
Applications
Unspecified application
Species
Unspecified reactive species
Cancer biotherapy & radiopharmaceuticals : PubMed32721218
2020
Applications
Unspecified application
Species
Unspecified reactive species
Cancer medicine 9:1115-1130 PubMed31823522
2019
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com